GARELVEO Trademark

Trademark Overview

On Monday, July 28, 2014, a trademark application was filed for GARELVEO with the United States Patent and Trademark Office. The USPTO has given the GARELVEO trademark a serial number of 86349904. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Tuesday, May 28, 2024. This trademark is owned by Glaxo Group Limited. The GARELVEO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
garelveo

General Information

Serial Number86349904
Word MarkGARELVEO
Filing DateMonday, July 28, 2014
Status710 - CANCELLED - SECTION 8
Status DateTuesday, May 28, 2024
Registration Number5332333
Registration DateTuesday, November 14, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 16, 2015

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateTuesday, May 28, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressStevenage SG12NY
GB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS

Trademark Events

Event DateEvent Description
Monday, November 10, 2014SUSPENSION LETTER WRITTEN
Thursday, July 31, 2014NEW APPLICATION ENTERED
Tuesday, August 5, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, November 10, 2014ASSIGNED TO EXAMINER
Monday, November 10, 2014LETTER OF SUSPENSION E-MAILED
Monday, November 10, 2014NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, April 30, 2015TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, May 4, 2015ASSIGNED TO LIE
Monday, May 11, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 11, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 12, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 12, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, May 27, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 16, 2015PUBLISHED FOR OPPOSITION
Tuesday, June 16, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 23, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 11, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, February 11, 2016SOU TEAS EXTENSION RECEIVED
Thursday, February 11, 2016SOU EXTENSION 1 FILED
Monday, March 14, 2016CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, March 14, 2016SOU EXTENSION 1 GRANTED
Tuesday, March 15, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 3, 2016SOU TEAS EXTENSION RECEIVED
Wednesday, August 3, 2016SOU EXTENSION 2 FILED
Tuesday, August 9, 2016SOU EXTENSION 2 GRANTED
Wednesday, August 10, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 1, 2017SOU TEAS EXTENSION RECEIVED
Wednesday, February 1, 2017SOU EXTENSION 3 FILED
Wednesday, February 1, 2017SOU EXTENSION 3 GRANTED
Friday, February 3, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 13, 2017TEAS DELETE 1(B) BASIS RECEIVED
Thursday, July 13, 2017NOTICE OF ALLOWANCE CANCELLED
Thursday, October 12, 20171(B) BASIS DELETED; PROCEED TO REGISTRATION
Tuesday, November 14, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, November 9, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, November 9, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 9, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 9, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, November 9, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 9, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, November 14, 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, August 11, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, August 11, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, August 11, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, August 11, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, August 11, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 28, 2024CANCELLED SEC. 8 (6-YR)

Related Keywords

garelveo pharmaceutical treatment disorders preparations substances diseases ophthalmic respiratory hepatological oncological